

Kam 09/407,605

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:44:45 ON 04 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2003 VOL 138 ISS 10

FILE LAST UPDATED: 3 Mar 2003 (20030303/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 17

L1 112 SEA FILE=REGISTRY ^ATG(GCC|CGC|AAC|GAC|GGC|GAG|CAG|TGC|CAC|ATC|CTG|AAG|ATG|TTC|CCC|AGC|ACC|TGG|TAC|GTG){150-}/SQSN

L6 7 SEA FILE=REGISTRY L1 AND ((104162-48-3/BI OR 57-88-5/BI OR 207241-25-6/BI OR 120178-12-3/BI OR 12629-01-5/BI OR 138415-12-0/BI OR 138415-13-1/BI OR 138756-33-9/BI OR 202484-87-5/BI OR 202484-88-6/BI OR 202484-89-7/BI OR 202484-90-0/BI OR 202485-77-6/BI OR 202485-78-7/BI OR 202485-79-8/BI OR 202485-80-1/BI OR 202485-81-2/BI OR 202485-82-3/BI OR 207241-26-7/BI OR 207241-27-8/BI OR 207241-29-0/BI OR 207241-30-3/BI OR 244145-68-4/BI OR 244145-69-5/BI OR 63-42-3/BI OR 9003-39-8/BI OR 102386-00-5/BI OR 105150-09-2/BI OR 123626-67-5/BI OR 187888-07-9/BI OR 194554-71-7/BI OR 207241-28-9/BI OR 209056-07-5/BI OR 209056-34-8/BI OR 211681-52-6/BI OR 244144-62-5/BI OR 244144-65-8/BI OR 244144-66-9/BI OR 244144-67-0/BI OR 244144-68-1/BI OR 244144-69-2/BI OR 244145-71-9/BI OR 244145-72-0/BI OR 244145-73-1/BI OR 244145-74-2/BI OR 244145-75-3/BI OR 244145-76-4/BI OR 244145-77-5/BI OR 245759-04-0/BI OR 245759-06-2/BI OR 245759-08-4/BI OR 257859-98-6/BI OR 257901-54-5/BI OR 257901-80-7/BI OR 257901-81-8/BI OR 257901-82-9/BI OR 257901-83-0/BI OR 257901-84-1/BI OR 257901-85-2/BI OR 257901-86-3/BI OR 257901-87-4/BI OR 257901-88-5/BI OR 257901-89-6/BI OR 257901-90-9/BI OR 257901-91-0/BI OR 258258-36-5/BI OR 258258-37-6/BI OR 258258-38-7/BI OR 321976-25-4/BI OR 353572-08-4/BI OR 475270-13-4/BI OR 475270-14-5/BI OR 475270-15-6/BI OR 475270-16-7/BI OR 475270-17-8/BI OR 475270-18-9/BI OR 475270-19-0/BI OR 475270-20-3/BI OR 475270-21-4/BI OR 475270-22-5/BI OR 475270-23-6/BI OR 475270-24-7/BI OR 475270-25-8/BI OR 475270-26-9/BI OR 475270-27-0/BI OR 475270-28-1/BI OR 475270-29-2/BI OR 475304-74-6/BI OR 475304-75-7/BI OR 475306-76-4/BI OR 475306-77-5/BI OR 475306-78-6/BI OR 475306-79-7/BI OR 475306-80-0/BI OR 475306-81-1/BI OR 475306-82-2/BI OR 475306-83-3/BI OR 475306-84-4/BI OR 475306-85-5/BI OR 475306-86-6/BI

L7 9 SEA FILE=HCAPLUS L6

Kam 09/407,605

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:45:28 ON 04 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2003 HIGHEST RN 496764-40-0
DICTIONARY FILE UPDATES: 2 MAR 2003 HIGHEST RN 496764-40-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNnote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sqide l6 1-7

L6 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 475304-75-7 REGISTRY
CN DNA (Ptilosarcus gurneyi green fluorescent protein gene plus 3'flank)
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO02090535 FIG: 3 claimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 717
NA 158 a 229 c 220 g 110 t

PATENT ANNOTATIONS (PNTE):

Sequence |Patent
Source |Reference

=====+=====

Not Given	WO2002090535
	claimed FIG
	3

SEQ	1	atg ^g ggc ^a aac ^b	gca ^a ac ^g tg ^t gct	gaagaacacc	ggcctgaagg	agatcatgag
		=====	=====	=====	=====	=====
	51	cgccaaggcc	agcgtggagg	gcatcgtgaa	caaccacgtg	ttcagcatgg
		=====	=====	=====	=====	=====
	101	agggcttcgg	caagggaac	gtgctgttcg	gcaaccagct	gatgcagatc
		=====	=====	=====	=====	=====
	151	cgcgtgacca	aggcgggccc	cctgcccttc	gccttcgaca	tcgtgagcat
		=====	=====	=====	=====	=====
	201	cgccttcag	tacggcaacc	gcaccttcac	caagtacccc	gacgacatcg
		=====	=====	=====	=====	=====
	251	ccgactactt	cgtgcagagc	ttccccgccg	gcttcttcta	cgagcgcaac
		=====	=====	=====	=====	=====
	301	ctgcgcttcg	aggacggcgc	catcgtggac	atccgcagcg	acatcagcct
		=====	=====	=====	=====	=====

```

351 ggaggacgac aagttccact acaaggtgga gtaccgcggc aacggcttcc
=====
401 ccagcaacgg ccccgatgat cagaaggcca tcctgggcat ggagcccagc
=====
451 ttcgaggtgg tgtacatgaa cagcggcgtg ctggtgggcg aggtggacct
=====
501 ggtgtacaag ctggagagcg gcaactacta cagctgccac atgaagacct
=====
551 tctaccgcag caagggcggc gtgaaggagt tccccgagta ccacttcac
=====
601 caccaccgcc tggagaagac ctacgtggag gagggcagct tcgtggagca
=====
651 gcacgagacc gccatcgccc agctgaccac catcggcaag cccctgggca
=====
701 gcctgcacga gtgggtg
=====

```

HITS AT: 1-717

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS

RN 353572-08-4 REGISTRY

CN DNA (synthetic complement decay-accelerating factor-specifying cDNA fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: JP2001211882 SEQID: 1 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 960

NA 188 a 394 c 267 g 111 t

PATENT ANNOTATIONS (PNTE):

Sequence |Patent

Source |Reference

=====+

Not Given|JP2001211882

|claimed

|SEQID 1

```

SEQ      1 atgaccgtgg cccgccccag cgtgcccgcc gccctgcccc tgctgggcga
=====
      51 gctgccccgc ctgctgctgc tgggtgctgct gtgctgccc gccgtgtggg
=====
     101 gccgcagctg cgaggtgccc acccgccctga acagcgccag cctgaagcag
=====
     151 ccctacatca cccagaacta cttccccgtg ggcaccgtgg tggagtacga
=====
     201 gtgccgcccc ggctaccgcc gcgagcccag cctgagcccc aagctgacct
=====
     251 gcctgcagaa cctgaagtgg agcaccgccg tggagtctct caagaagaag
=====
     301 agctgccccca accccggcga gatccgcaac ggccagatcg acgtgcccgg
=====
     351 cggcatcctg ttcggcgcca ccatcagctt cagctgcaac accggctaca
=====

```

```

401 agctgttcgg cagcaccagc agcttctgcc tgatcagcgg cagcagcgtg
=====
451 cagtggagcg accccctgcc cgagtgccgc gagatctact gccccgcccc
=====
501 cccccagatc gacaacggca tcatccaggg cgagcgcgac cactacggct
=====
551 accgccagag cgtgacctac gcctgcaaca agggcttcac catgatcggc
=====
601 gagcacagca tctactgcac cgtgaacaac gacgagggcg agtggagcgg
=====
651 cccccccccc gagtgccgcg gcaagagcct gaccagcaag gtgcccccca
=====
701 ccgtgcagaa gcccaccacc gtgaacgtgc ccaccaccga ggtgagcccc
=====
751 accagccaga agaccaccac caagaccacc accccaacg cccaggccac
=====
801 ccgcagcacc cccgtgagcc gcaccacca gcacttccac gagaccacc
=====
851 ccaacaaggg cagcggcacc accagcggca ccaccgcct gctgagcggc
=====
901 cacacctgct tcacctgac cggcctgctg ggcaccctgg tgaccatggg
=====
951 cctgctgacc
=====

```

HITS AT: 1-960

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS

RN **258258-38-7** REGISTRY

CN DNA (synthetic human angiostatin-specifying) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5: PN: WO0006759 PAGE: 40 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 1362

NA 320 a 520 c 383 g 139 t

PATENT ANNOTATIONS (PNTE):

Sequence |Patent

Source |Reference

=====+

Not Given|WO2000006759

|claimed PAGE

|40

```

SEQ      1 atggagcaca aggaggtggt gctgctgctg ctgctgttcc tgaagagcgg
=====
      51 ccagggcgag cccctggacg actacgtgaa caccagggc gccagcctgt
=====
     101 tcagcgtgac caagaagcag ctgggcgccg gcagcatcga ggagtgcgcc
=====
     151 gccaaagtgcg aggaggacga ggagttcacc tgccgcgcct tccagtacca
=====

```

```

=====
201 cagcaaggag cagcagtgcg tgatcatggc cgagaaccgc aagagcagca
=====
251 tcatcatccg catgcgcgac gtggtgctgt tcgagaagaa ggtgtacctg
=====
301 agcgagtgca agaccggcaa cggcaagaac taccgcggca ccatgagcaa
=====
351 gaccaagaac ggcacacact gccagaagtg gagcagcacc agccccacc
=====
401 gcccccgctt cagccccgcc acccacccca gcgagggcct ggaggagaac
=====
451 tactgccgca accccgacaa cgacccccag ggccccctgt gctacaccac
=====
501 cgacccccgag aagcgctacg actactgcga catcctggag tgcgaggagg
=====
551 agtgcattgca ctgcagcggc gagaactacg acggcaagat cagcaagacc
=====
601 atgagcggcc tggagtgcc a ggctgggac agccagagcc cccacgcccc
=====
651 cggctacatc cccagcaagt tccccaaaca gaacctgaag aagaactact
=====
701 gccgcaaccc cgaccgcgag ctgcgcccct ggtgcttcac caccgacccc
=====
751 aacaagcgct gggagctgtg cgacatcccc cgctgcacca ccccccccc
=====
801 cagcagcggc cccacctacc agtgctgaa gggcaccggc gagaactacc
=====
851 gcggcaacgt ggccgtgacc gtgagcggcc acacctgcca gactggagc
=====
901 gccagaccc cccacacca caaccgcacc cccgagaact tccccgcaa
=====
951 gaacctggac gagaactact gccgcaaccc cgacggcaag cgcgccccct
=====
1001 ggtgccacac caccaacagc caggtgcgct gggagtactg caagatcccc
=====
1051 agctgcgaca gcagccccgt gagcaccgag cagctggccc ccaccgcccc
=====
1101 ccccgagctg acccccgctg tgcaggactg ctaccacggc gacggccaga
=====
1151 gctaccgcgg caccagcagc accaccacca ccggcaagaa gtgccagagc
=====
1201 tggagcagca tgacccccca ccgccaccag aagacccccg agaactacct
=====
1251 caacgccggc ctgaccatga actactgcc caaccccgac gccgacaagg
=====
1301 gccccctgtg cttcaccacc gaccccgagc tgcgctggga gtactgcaac
=====
1351 ctgaagaagt gc
=====
=====

```

HITS AT: 1-1362

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS

RN 211681-52-6 REGISTRY

CN DNA (synthetic clone pIL0550B gene IL-2) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 462
 NA 113 a 157 c 122 g 70 t

```

SEQ      1 atgtaccgca tgcagctgct gagctgcatc gccctgagcc tggccctggt
          =====
          51 gaccaacagc gccccaccca gcagcagcac caagaagacc cagctgcagc
             =====
         101 tggagcacct gctgctggac ctgcagatga tctgaacgg catcaacaac
             =====
         151 tacaagaacc ccaagctgac ccgcatgctg accttcaagt tctacatgcc
             =====
         201 caagaaggcc accgagctga agcacctgca gtgcctggag gaggagctga
             =====
         251 agcccctgga ggaggtgctg aacctggccc agagcaagaa cttccacctg
             =====
         301 cgcccccgcg acctgatcag caacatcaac gtgatcgtgc tggagctgaa
             =====
         351 gggcagcgag accaccttca tgtgcgagta cgccgacgag accgccacca
             =====
         401 tcgtggagtt cctgaaccgc tggatcacct tctgccagag catcatcagc
             =====
         451 accctgacct ga
             =====
  
```

HITS AT: 1-459

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN **209056-07-5** REGISTRY
 CN DNA (synthetic human insulin-like growth factor I cDNA) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 462
 NA 89 a 176 c 134 g 63 t

```

SEQ      1 atgggcaaga tcagcagcct gccacccag ctgttcaagt gctgcttctg
          =====
          51 cgacttctctg aaggtgaaga tgcacaccat gagcagcagc cacctgttct
             =====
         101 acctggccct gtgcctgctg accttcacca gcagcgccac cgccggcccc
             =====
         151 gagaccctgt gcggcgccga gctggtggac gccctgcagt tcgtgtgcgg
             =====
         201 cgaccgcggc ttctacttca acaagcccac cggctacggc agcagcagcc
             =====
         251 gccgcgcccc ccagaccggc atcgtggacg agtgctgctt ccgcagctgc
             =====
         301 gacctgcgcc gcctggagat gtactgcgcc cccctgaagc ccgccaagag
             =====
         351 cgcccgcgagc gtgcgcgccc agcgccacac cgacatgccc aagaccgaga
             =====
  
```

```

401 aggaggtgca cctgaagaac gccagccgcg gcagcgccgg caacaagaac
=====
451 taccgcatgt ga
=====

```

HITS AT: 1-459

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN 207241-26-7 REGISTRY
 CN DNA (synthetic human interleukin 12 p40 subunit cDNA) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN DNA (human interleukin 12 p40 subunit synthetic gene)
 CN PN: WO9947678 SEQID: 3 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 987
 NA 220 a 324 c 318 g 125 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO9947678
	claimed
	SEQID 3

```

SEQ      1 atgtgccacc agcagctggt gatcagctgg ttcagcctgg tgttcctggc
=====
      51 cagccccctg gtggccatct gggagctgaa gaaggacgtg tacgtggtgg
=====
     101 agctggactg gtaccccgac gccccggcg agatggtggt gctgacctgc
=====
     151 gacacccccg aggaggacgg catcacctgg accctggacc agagcagcga
=====
     201 ggtgctgggc agcggcaaga ccctgaccat ccaggtgaag gagttcggcg
=====
     251 acgccggcca gtacacctgc cacaagggcg gcgagggtgct gagccacagc
=====
     301 ctgctgctgc tgcacaagaa ggaggacggc atctggagca ccgacatcct
=====
     351 gaaggaccag aaggagccca agaacaagac cttcctgcgc tgcgaggcca
=====
     401 agaactacag cggccgcttc acctgctggt ggctgaccac catcagcacc
=====
     451 gacctgacct tcagcgtgaa gagcagcagg ggcagcagcg acccccaggg
=====
     501 cgtgacctgc ggcgccgcca ccctgagcgc cgagcgctg cgcggcgaca
     551 acaaggagta cgagtacagc gtggagtgcc aggaggacag cgcctgcccc
     601 gccgccgagg agagcctgcc catcgagggt atggtggacg ccgtccacaa
     651 gctgaagtac gagaactaca ccagcagctt cttcatccgc gacatcatca
     701 agccccgacc cccaagaac ctgcagctga agcccctgaa gaacagccgc

```

```

751 caggtggagg tgagctggga gtaccccgac acctggagca cccccacag
801 ctacttcagc ctgaccttct gcgtgcaggt gcagggcaag agcaagcgcg
851 agaagaagga ccgcgtgttc accgacaaga ccagcgccac cgtgatctgc
901 cgcaagaacg ccagcatcag cgtgcgcgcc caggaccgct actacagcag
951 cagctggagc gagtgggcca gcgtgccctg cagctag

```

HITS AT: 1-477

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L6 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS

RN 202485-81-2 REGISTRY

CN DNA (synthetic mammalian codon-optimized human terminal
 deoxyribonucleotidyltransferase (telomeric DNA) subunit p105 cDNA) (9CI)
 (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 2277

NA 557 a 723 c 781 g 216 t

```

SEQ      1 atggccggcc tgaccctgtt cgtgggcccgc ctgcccccca gcgcccgcag
          =====
          51 cgagcagctg gaggagctgt tcagccaggt gggccccgtg aagcagtgt
          =====
         101 tcgtggtgac cgagaagggc agcaaggcct gccgcggctt cggctacgtg
          =====
         151 accttcagca tgctggagga cgtgcagcgc gccctgaagg agatcaccac
          =====
         201 cttcgagggc tgcaagatca acgtgaccgt ggccaagaag aagctgcgca
          =====
         251 acaagaccaa ggagaagggc aagaacgaga acagcgagtg cccaagaag
          =====
         301 gagcccaagg ccaagaaggc caaggtggcc gacaagaagg cccgcctgat
          =====
         351 catccgcaac ctgagcttca agtgcagcga ggacgacctg aagaccgtgt
          =====
         401 tcgcccagtt cggcgccgtg ctggaggtga acatcccccg caagcccagc
          =====
         451 ggcaagatgc gcggttcggt cttcgtgcag ttcaagaacc tgctggaggc
          =====
         501 cggcaaggcc ctgaagggca tgaacatgaa ggagatcaag ggccgcaccg
          =====
         551 tggccgtgga ctgggccgtg gccaaggaca agtacaagga caccagagc
          =====
         601 gtgagcgcca tcggcgagga gaagagccac gagagcaagc accaggagag
          =====
         651 cgtgaagaag aagggccgcg aggaggagga catggaggag gaggagaacg
          =====
         701 acgacgacga cgacgacgac gacgaggagg acggcgtgtt cgacgacgag
          =====
         751 gacgaggagg aggagaacat cgagagcaag gtgaccaagc ccgtgcagat
          =====
         801 ccagaagcgc gccgtgaagc gccccgcccc cgccaagagc agcgaccaca
          =====
         851 gcgaggagga cagcgacctg gaggagagcg acagcatcga cgacggcgag

```



```

=====
901 gagctggccc agagcgacac cagcaccgag gagcaggagg acaaggccgt
=====
951 gcaggtgagc aacaagaaga agcgcaagct gcccagcgac gtgaacgagg
=====
1001 gcaagaccgt gttcatccgc aacctgagct tcgacagcga ggaggaggag
=====
1051 ctgggcgagc tgctgcagca gttcggcgag ctgaagtacg tgcgcacgt
=====
1101 gctgcacccc gacaccgagc acagcaaggg ctgcgccttc gcccagttca
=====
1151 tgaccaggga ggccgcccag aagtgcctgc tggccgccag ccccgagaac
=====
1201 gaggccggcg gcctgaagct ggacggccgc cagctgaagg tggacctggc
=====
1251 cgtgaccgcg gacgaggccg ccaagctgca gaccaccaag gtgaagaagc
=====
1301 ccaccggcac ccgcaacctg tacctggccc gcgagggcct gatccgcgcc
=====
1351 ggcaccaagg ccgccgaggg cgtgagcgcc gccgacatgg ccaagcgcgga
=====
1401 gcgcttcgag ctgctgaagc accagaagct gaaggaccag aacatcttcg
=====
1451 tgagccgcac ccgcctgtgc ctgcacaacc tgcccaaggc cgtggacgac
=====
1501 aagcagctgc gcaagctgct gctgagcgcc accagcgcgc agaagggcgt
=====
1551 gcgcatcaag gagtgccgcg tgatgcgcga cctgaagggc gtgcacggca
=====
1601 acatgaaggg ccagagcctg ggctacgctt tcgccgagtt ccaggagcac
=====
1651 gagcacgccc tgaaggccct gcgcctgata aacaacaacc ccgagatctt
=====
1701 cgcccccttg aagcgcccca tcgtggagtt cagcctggag gaccgccgca
=====
1751 agctgaagat gaaggagctg cgcattccagc gcagcctgca gaagatgcgc
=====
1801 agcaagcccc ccaccggcga gcccagaag ggccagcccc agccccccaa
=====
1851 ggaccagcag cagaaggccg cccagcacca caccgaggag cagagcaagg
=====
1901 tgccccccga gcagaagcgc aaggccggca gcaccagctg gaccggcttc
=====
1951 cagaccaagg ccgaggtgga gcaggtggag ctgcccagcg gcaagaagcg
=====
2001 ccgcaaggtg ctggccctgc ccagccaccg cgcccccaag atccgcctgc
=====
2051 gcgacaaggg caaggtgaag cccgtgcacc ccaagaagcc caagccccag
=====
2101 atcaaccagt ggaagcagga gaagcagcag ctgagcagcg agcaggtgag
=====
2151 ccgcaagaag gccaaaggga acaagaccga gaccgccttc aaccagctgg
=====
2201 tggagcagta caagcagaag ctgctgggcc ccagcaaggg cgcccccttg
=====
2251 gccaaagcga gcaagtgggt cgacagc
=====

```

HITS AT: 1-2277

Kam 09/407,605

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:46:28 ON 04 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2003 VOL 138 ISS 10
FILE LAST UPDATED: 3 Mar 2003 (20030303/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l7 1-9 ibib abs hitrn

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:869075 HCAPLUS
DOCUMENT NUMBER: 137:365327
TITLE: The green fluorescent proteins of Renilla and Ptilosarcus and their use as reporter molecules
INVENTOR(S): Anderson, David
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090535	A1	20021114	WO 2002-US14766	20020509
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2001-290287P P 20010510
 US 2002-133973 A2 20020424

AB The invention relates to methods and compns. utilizing Renilla green fluorescent proteins (rGFP), and Ptilosarcus green fluorescent proteins (pGFP). In particular, the invention relates to the use of Renilla GFP or Ptilosarcus GFP proteins as reporters for cell assays, particularly intracellular assays, including methods of screening libraries, using rGFP or pGFP.

IT **475304-75-7**

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (nucleotide sequence; green fluorescent proteins of Renilla and Ptilosarcus and their use as reporter mols.)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:568202 HCAPLUS

DOCUMENT NUMBER: 135:163357

TITLE: Expression of human codon modified DAF gene in mammalian cells for reducing transplant rejection

INVENTOR(S): Miyagawa, Shuji

PATENT ASSIGNEE(S): Nippon Meat Packers, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001211882	A2	20010807	JP 2000-22784	20000131
PRIORITY APPLN. INFO.:			JP 2000-22784	20000131

AB This invention provides codon modified human complement decay-accelerating factor (DAF) gene which was expressed in transgenic mouse. The codon modification of transplant related genes is used to increase the expression of these genes in discordant transplant donor to reduce rejection reaction during transplants. The method described in this invention can be used to rejection reaction, blood coagulation and reperfusion of hypoemia.

IT **353572-08-4**

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(nucleotide sequence; Expression of human codon modified DAF gene in mammalian cells for reducing rejection in transplant)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:98808 HCAPLUS

DOCUMENT NUMBER: 132:146634

TITLE: Anti-angiogenesis plasmids and delivery systems and their construction and use

INVENTOR(S): Min, Wang; Szymanski, Paul; Mehrens, Dorothy; Ralston, Robert; Sullivan, Sean

PATENT ASSIGNEE(S): Valentis, Inc., USA

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006759	A2	20000210	WO 1999-US16388	19990720
WO 2000006759	A3	20000622		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337496	AA	20000210	CA 1999-2337496	19990720
AU 9953182	A1	20000221	AU 1999-53182	19990720
EP 1100941	A2	20010523	EP 1999-938769	19990720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002524036	T2	20020806	JP 2000-562541	19990720
PRIORITY APPLN. INFO.:			US 1998-94375P	P 19980727
			WO 1999-US16388	W 19990720
AB	<p>The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of anti-angiogenic agents in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for prepg. and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic anti-angiogenic encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably interleukin-12), as well as methods for prepg. such constructs. Plasmid vectors are constructed comprising synthetic genes having optimal codon usage for endostatin and angiostatin expression, under the control of a promoter specific for expression in endothelial cells (e.g., the enhancer of cytomegalovirus for human endothelin-1) and the growth hormone 3'-untranslated region with a deleted Alu repeat. A polymeric gene delivery system uses polyvinyl pyrrolidone to increase protein expression by protecting plasmid DNA from nucleases and controlling the dispersion and retention of plasmid DNA in injected tissues. The plasmid delivery system also comprises a cationic lipid (DOPTMA), neutral lipid (cholesterol), and an isotonic carbohydrate (lactose) soln.</p>			
IT	<p>258258-38-7 RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleotide sequence; anti-angiogenesis plasmids and delivery systems and their construction and use)</p>			
L7	ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2003 ACS			
ACCESSION NUMBER:	1999:614138 HCAPLUS			
DOCUMENT NUMBER:	131:238811			
TITLE:	Expression vectors for interferon .alpha. genes for use in gene therapy			
INVENTOR(S):	Nordstrom, Jeff; Pericle, Federica; Rolland, Allain;			

PATENT ASSIGNEE(S): Ralston, Robert
 SOURCE: Genemedicine, Inc., USA
 PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947678	A2	19990923	WO 1999-US5394	19990312
WO 9947678	A3	19991209		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2323604	AA	19990923	CA 1999-2323604	19990312
AU 9930003	A1	19991011	AU 1999-30003	19990312
EP 1064383	A2	20010103	EP 1999-911340	19990312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506647	T2	20020305	JP 2000-536861	19990312
PRIORITY APPLN. INFO.:			US 1998-78654P	P 19980319
			WO 1999-US5394	W 19990312
AB	Plasmid expression constructs for mammalian interferon .alpha. genes that can be used in gene therapy and methods for delivering them are described. These constructs can be used in the treatment of cancer, including combination therapy with other agents, such as cytokines, preferably IL-12. Constructs using a cytomegalovirus promoter, a synthetic 5'-intron and the 3'-UTR of the human growth hormone gene are described. The interferon .alpha. genes may have its codon usage altered to maximize or increase expression. Direct administration of a mouse interferon .alpha.4 gene to renal cell carcinomas and mammary cell adenocarcinomas was shown to inhibit tumor growth, and bring about complete complete regression in some cases. The treatment also induced long-lasting immunity to secondary tumor challenges.			
IT	207241-26-7 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleotide sequence; expression vectors for interferon .alpha. genes for use in gene therapy)			
L7	ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2003 ACS			
ACCESSION NUMBER:	1998:550439 HCAPLUS			
DOCUMENT NUMBER:	129:185076			
TITLE:	IL-2 gene expression, liposome delivery system, and uses			
INVENTOR(S):	Ralston, Robert; Muller, Susanne; Mumper, Russ; Munger, William; Bruno, Maria			
PATENT ASSIGNEE(S):	Genemedicine, Inc., USA			
SOURCE:	PCT Int. Appl., 77 pp. CODEN: PIXXD2			
DOCUMENT TYPE:	Patent			

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834952	A2	19980813	WO 1998-US2221	19980209
WO 9834952	A3	19990114		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6034072	A	20000307	US 1998-12366	19980123
AU 9862692	A1	19980826	AU 1998-62692	19980209
EP 975780	A2	20000202	EP 1998-904943	19980209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001511647	T2	20010814	JP 1998-534889	19980209
PRIORITY APPLN. INFO.:				
			US 1997-39709P	P 19970210
			US 1998-12366	A 19980123
			WO 1998-US2221	W 19980209
AB	Plasmid expression systems for delivery of DNA coding sequences in liposomes to a mammal are described which provide expression of human IL-2 for therapy of cancers and other diseases. Also described are particular lipid/DNA delivery systems having advantageous characteristics of size, charge ratio, and proportion of supercoiled DNA, and methods of prep. and using such delivery systems for treatment.			
IT	211681-52-6, DNA (synthetic clone pIL0550B gene IL-2) RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (nucleotide sequence; IL-2 gene expression, liposome delivery system, and uses)			
L7	ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2003 ACS			
ACCESSION NUMBER:	1998:398430 HCAPLUS			
DOCUMENT NUMBER:	129:64088			
TITLE:	Insulin-like growth factor I (IGF-I) expression vector for gene therapy			
INVENTOR(S):	Coleman, Michael; Schwartz, Robert; Demayo, Francesco J.			
PATENT ASSIGNEE(S):	GeneMedicine, Inc., USA; Baylor College of Medicine			
SOURCE:	PCT Int. Appl., 116 pp. CODEN: PIXXD2			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824922	A1	19980611	WO 1997-US21852	19971201
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,				

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9853662 A1 19980629 AU 1998-53662 19971201

EP 943003 A1 19990922 EP 1997-950737 19971201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

JP 2001505435 T2 20010424 JP 1998-525696 19971201

US 2003018984 A1 20030123 US 2001-861101 20010518

PRIORITY APPLN. INFO.:

US 1996-31539P P 19961202

US 1997-974572 A 19971119

WO 1997-US21852 W 19971201

AB This invention relates to gene delivery and expression, including gene therapy, by using vectors which encode stable mRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant IGF-I genes within tissues at certain levels. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3' flanking region including a 3' UTR and/or 3' NCR, and a linker which connects the 5' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3' flanking region is 3' to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating. Expression plasmids containing chicken skeletal muscle α -actin gene promoter and first intron, human IGF-I cDNA and human growth hormone gene 3'-UTR and poly(A) signal were prepared. Replacement of skeletal muscle α -actin gene 3'-UTR of prior art plasmids with the 3'-UTR of human growth hormone (as above) resulted in increased delivery of IGF-I from skeletal muscle to systemic circulation in both transgenic animal (mouse) and non-viral gene therapy paradigms. The vector was nontoxic in safety/toxicology studies in dogs. Use of the vector in treatment of diabetes (in rats) and (calf) muscle disuse atrophy was demonstrated.

IT 209056-07-5

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(nucleotide sequence; insulin-like growth factor I expression vector for gene therapy)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:268632 HCAPLUS

DOCUMENT NUMBER: 129:50507

TITLE: Polycistronic expression constructs for gene therapy using interleukin 12 genes and their delivery by liposomes

INVENTOR(S): Nordstrom, Jeff; Freimark, Bruce; Deshpande, Deepa

PATENT ASSIGNEE(S): Genemedicine, Inc., USA; Nordstrom, Jeff; Freimark, Bruce; Deshpande, Deepa

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817814	A2	19980430	WO 1997-US18832	19971010
WO 9817814	A3	19980827		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749081	A1	19980515	AU 1997-49081	19971010
EP 931156	A2	19990728	EP 1997-911788	19971010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001503258	T2	20010313	JP 1998-519520	19971010
US 2002119940	A1	20020829	US 2001-754014	20010103
PRIORITY APPLN. INFO.:			US 1996-28687P	P 19961018
			US 1997-948958	B1 19971010
			WO 1997-US18832	W 19971010
AB Plasmid expression vectors for delivery of genes for a heterooligomeric proteins that ensure coordinated expression of the genes are described for use in gene therapy. In particular, these vectors use synthetic introns and 5'- and 3'-untranslated regions to control expression. These sequences are designed to have good fits with consensus sequences for important functional sequences such as Kozak boxes and intron cleavage and splice sites. Also described are particular lipid/DNA delivery systems having advantageous characteristics of size, charge ratio, and proportion of supercoiled DNA, and methods of prep. and using such delivery systems for treatment or as immunization adjuvants. Optimization expts. are described. Studies with a guinea pig model of asthma showed that liposomes of the expression cassette introduced into the bronchi could be used to reduce the inflammatory response.				
IT 207241-26-7 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (nucleotide sequence; polycistronic expression constructs for gene therapy using interleukin 12 genes and their delivery by liposomes)				
L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1998:65983 HCAPLUS DOCUMENT NUMBER: 128:150393 TITLE: Purification and recombinant production of human telomerase subunits and their applications for drug screening and therapy INVENTOR(S): Cao, Zhaodan PATENT ASSIGNEE(S): Tularik, Inc., USA SOURCE: PCT Int. Appl., 33 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801543	A1	19980115	WO 1997-US12297	19970708

W: AU, CA, JP

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5747317 A 19980505 US 1996-676967 19960708

AU 9738829 A1 19980202 AU 1997-38829 19970708

US 5888747 A 19990330 US 1998-72270 19980504

PRIORITY APPLN. INFO.: US 1996-676967 19960708

WO 1997-US12297 19970708

AB The invention provides methods and compns. relating to a human telomerase and related nucleic acids, including 4 distinct human telomerase subunit proteins called p140, p105, p48 and p43 having human telomerase-specific activity. Human telomerase p105 subunit cDNA contains an open reading frame encoding 759 amino acids. The proteins may be produced recombinantly from transformed host cells from the disclosed telomerase encoding nucleic acids or purified from human cells. Also included are human telomerase RNA components, as well as specific, functional derivs. thereof. The invention provides isolated telomerase hybridization probes and primers capable of specifically hybridizing with the disclosed telomerase gene, telomerase-specific binding agents such as specific antibodies, and methods of making and using the subject compns. in diagnosis, therapy and in the biopharmaceutical industry.

IT 202485-81-2

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(nucleotide sequence; purifn. and recombinant prodn. of human telomerase subunits and their applications for drug screening and therapy)

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:65982 HCAPLUS

DOCUMENT NUMBER: 128:151114

TITLE: Purification and recombinant production of human telomerase subunits and their applications for drug screening and therapy

INVENTOR(S): Collins, Kathleen

PATENT ASSIGNEE(S): Regents of the University of California, USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801542	A1	19980115	WO 1997-US12296	19970708
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5770422	A	19980623	US 1996-676974	19960708
AU 9737281	A1	19980202	AU 1997-37281	19970708
US 5917025	A	19990629	US 1998-98487	19980616
PRIORITY APPLN. INFO.:			US 1996-676974	19960708
			WO 1997-US12296	19970708

AB The invention provides methods and compns. relating to a human telomerase

and related nucleic acids, including 4 distinct human telomerase subunit proteins called p140, p105, p48 and p43 having human telomerase-specific activity. Human telomerase p105 subunit cDNA contains an open reading frame encoding 759 amino acids. The proteins may be produced recombinantly from transformed host cells from the disclosed telomerase encoding nucleic acids or purified from human cells. Also included are human telomerase RNA components, as well as specific, functional derivs. thereof. The invention provides isolated telomerase hybridization probes and primers capable of specifically hybridizing with the disclosed telomerase gene, telomerase-specific binding agents such as specific antibodies, and methods of making and using the subject compns. in diagnosis, therapy and in the biopharmaceutical industry.

IT 202485-81-2

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(nucleotide sequence; purifn. and recombinant prodn. of human telomerase subunits and their applications for drug screening and therapy)